Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma

Annals of Oncology

Volumn 13, Issue 9, 2002, Pages 1430-1437

  Berglund, A ^a   Molin, D ^a   Larsson, A ^b   Einarsson, R ^c   Glimelius, B ^a  

^a Melanoma Patient Network Europe   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c AB Sangtec Medical   (Sweden)

Author keywords

bFGF; CEA; Colorectal carcinoma; Palliative chemotherapy; TPS; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; IRINOTECAN; OXALIPLATIN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0036739136     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf220     Document Type: Article

References (45)

1. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282-308.
2. Assersohn L, Norman A, Cunningham D et al. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 1999; 79: 1800-1805.
3. Graf W, Bergstrom R, Pahlman L, Glimelius B. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur J Cancer 1994; 4: 453-457.
4. Köhne C-H, Cunningham D, Di Costanzo F et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
5. Gold PF. Specific carcinoembryonic antigens of the human digestive tract. J Exp Med 1965; 122: 467-481.
6. Hamm CM, Cripps C. Carcinoembryonic antigen in metastatic colorectal cancer. Clin Invest Med 1998; 21: 186-191.
7. Mitchell EP. Role of carcinoembryonic antigen in the management of advanced colorectal cancer. Semin Oncol 1998; 25: 12-20.
8. Macdonald JS. Carcinoembryonic antigen screening: pros and cons. Semin Oncol 1999; 26: 556-560.
9. Polito M, Minardi D, Recchioni A et al. Serum markers for monitoring of prostatic carcinoma. Prostate 1997; 33: 208-216.
10. Rebhandl W, Paya K, Felberbauer FX et al. Tissue polypeptide-specific antigen (TPS) in pediatric malignancies. Anticancer Res 1997; 17: 2865-2868.
11. Kornek G, Schenk T, Raderer M et al. Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. Br J Cancer 1995; 71: 182-185.
12. Mishaeli M, Klein B, Sadikov E et al. Initial TPS serum level as an indicator of relapse and survival in colorectal cancer. Anticancer Res 1998; 18: 2101-2105.
13. Zygmunt A, Madry R, Markowska J, Fischer Z. Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer. Eur J Gynaecol Oncol 1999; 20: 298-301.
14. Abbasciano V, Sartori S, Trevisani L et al. Neuron-specific enolase, thymidine kinase, and tissue polypeptide-specific antigen in diagnosis and response to chemotherapy of small-cell lung cancer. Cancer Detect Prev 1999; 23: 309-315.
15. Glimelius B, Hoffman K, Einarsson R et al. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. Acta Oncol 1996; 35: 141-148.
16. Rydlander L, Ziegler E, Bergman T et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996; 241: 309-314.
17. Brattstrom D, Bergqvist M, Larsson A et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 1998; 18: 1123-1127.
18. Dirix LY, Vermeulen PB, Hubens G et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996; 7: 843-848.
19. Davies MM, Jonas SK, Kaur S, Allen-Mersh TG. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume. Br J Cancer 2000; 82: 1004-1008.
20. Dirix LY, Vermeulen PB, Pawinski A et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997; 76: 238-243.
21. Fujisaki K, Mitsuyama K, Toyonaga A et al. Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998; 93: 249-252.
22. Kumar H, Heer K, Lee PW et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4: 1279-1285.
23. Takeda A, Shimada H, Imaseki H et al. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep 2000; 7: 333-338.
24. Hyodo I, Doi T, Endo H et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998; 34: 2041-2045.
25. Glimelius B. Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Ann Oncol 1993; 4: 235-240.
26. Glimelius B, Jakobsen A, Graf W et al. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Eur J Cancer 1998; 34: 674-678.
27. Graf W, Pahlman L, Bergstrom R, Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994; 70: 559-563.
28. Glimelius B, Hoffman K, Graf W et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 1994; 73: 556-562.
29. Glimelius B, Graf W, Hoffman K et al. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study. Acta Oncol 1992; 31: 645-651.
30. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1989; 7: 1437-1446.
31. Ray P, Quantin X, Grenier J et al. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev 1998; 22: 293-304.
32. van Dalen A. TPS monitoring in metastatic breast cancer. Int J Biol Markers 1999; 14: 45-48.
33. Al-Sarraf M, Baker L, Talley RW et al. The value of serial carcino-embryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy. Cancer 1979; 44: 1222-1225.
34. Allen-Mersh TG, Kemeny N, Niedzwiecki D et al. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 1987; 28: 1625-1629.
35. Herrera MA, Chu TM, Holyoke ED, Mittelman A. CEA monitoring of palliative treatment for colorectal carcinoma. Ann Surg 1977; 185: 23-30.
36. Hine KR, Dykes PW. Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA. Gut 1984; 25: 682-688.
37. Mayer RJ, Garnick MB, Steele GD Jr, Zamcheck N. Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer 1978; 42: 1428-1433.
38. Ravry M, Moertel CG, Schutt AJ, Go VL. Usefulness of serial serum carcinoembryonic antigen (CEA) determinations during anticancer therapy or long-term follow-up of gastrointestinal carcinoma. Cancer 1974; 34: 1230-1234.
39. Shani A, O'Connell MJ, Moertel CG et al. Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med 1978; 88: 627-630.
40. Staab HJ, Anderer FA, Hornung A et al. Doubling time of circulating CEA and its relation to survival of patients with recurrent colorectal cancer. Br J Cancer 1982; 46: 773-781.
41. Hanke B, Riedel C, Lampert S et al. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol 2001; 12: 221-226.
42. ASCO. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1998; 16: 793-795.
43. Verheul HM, Pinedo HM. Tumor growth: a putative role for platelets? Oncologist 1998; 3: II.
44. Buyse M, Thirion P, Carlson RW et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356: 373-378.
45. Nygren P, Glimelius B. The Swedish Council on Technology Assessment in Health Care (SBU) report on Cancer Chemotherapy - Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation. Acta Oncol 2001; 40: 155-165.